ARVINAS, INC.
NEW HAVEN, CT · Founded 2014 · CIK 0001655759 · Biotech · Private
AR-targeting PROTAC molecules that degrade androgen receptor proteins for castration-resistant prostate cancer treatment
arvinas.com →- Grants
- $1.1M
- 2 awards
- Sector median: 1
- Raised
- $129M
- 3 Form D · Jul 2019
- 87 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $41,609,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer | $648,400 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer | $402,226 | |
| Private capital raised | Form D · SEC | $55,000,000 | |
| Private capital raised | Form D · SEC | $32,499,996 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2118 | PIXIMUNE, INC. | — | — |
| 2119 | DFI Holding Inc. | — | $55M |
| 2120 | Sonoma Biotherapeutics | — | $265M |
| 2121 | ARVINAS, INC. | — | $129M |
| 2122 | ARBOR EQUITY GROUP FUND I, LP | — | $500K |
| 2123 | Indapta Therapeutics Inc. | — | $84M |
| 2124 | PERIOMICS CARE LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Sean CassidyExecutive Officer
- John HoustonDirector · Executive Officer
- Edward Kennedy, Jr.Director
- Andrew LevinDirector
- Manuel LitchmanDirector · Executive Officer
- Jakob LovenDirector
- Brad MargusDirector
- Bradley MargusDirector
- Briggs MorrisonDirector
- Kush ParmarDirector
- Liam RatcliffeDirector
- Tim ShannonDirector
- Timothy ShannonDirector
- Jonathan SoderstromDirector
- Stephen SquintoDirector
- Ian TaylorExecutive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.